1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag

Change in number of shares and votes in SynAct Pharma AB

LHFI

SynAct Pharma AB (the "Company") announces that the number of shares and votes has increased by 5,191,003 as a result of the directed share issues resolved upon by the extraordinary general meeting on 13 December 2024.

Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 46,487,467.

For further information, please contact:
Jeppe Øvlesen, CEO SynAct Pharma
Tel: +45 2844 7567
Email: JOO@synactpharma.com 

About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.

This information is information that SynAct Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-12-30 18:45 CET.

Attachments
Change in number of shares and votes in SynAct Pharma AB

Datum 2024-12-30, kl 18:45
Källa MFN
Bifogade filer
Change in number of shares and votes in SynAct Pharma AB
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.